Comparing the effects of Omega-3 Fatty Acids Supplement and Placebo in the treatment Patients with Methamphetamine-Induced Mood Disorder

The efficacy of Omega-3 Fatty Acids Supplement in the treatment Patients with Methamphetamine-Induced Mood Disorder compared with placebo in amphetamine Users (clinical trial with a control group)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150822023705N13

Enrollment

Registered

2020-11-23

Start date

2020-12-25

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine-Induced Mood Disorder. Other stimulant use, unspecified with stimulant-induced mood disorder

Interventions

Intervention 1: Intervention group: The group will receive Omega-3 Fatty Acids Supplement treatment in two months. The daily dose will be 1 capsule of 1000 mg. These capsules will be given to patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Methamphetamine dependence diagnoses according to Diagnostic and Statistical Manual of Mental Disorders fifth edition and TLC test Methamphetamine-Induced Mood Disorder diagnoses accordingly Diagnostic and Statistical Manual of Mental Disorders fifth edition by a psychiatrist The dominant use of methamphetamine for at least 6 months Lack of serious psychiatric disorders

Exclusion criteria

Exclusion criteria: Disagreement to participate in the study

Design outcomes

Primary

Measure	Time frame
Relapse. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: relapse Questionnaire.;Craving. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: craving Questionnaire.;Withdrawal symptoms. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: withdrawal symptoms Questionnaire.;Depression. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: depression Questionnaire.;Mania. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: mania Questionnaire.;Anxiety. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: anxiety Questionnaire.;Sleep quality. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: sleep quality Questionnaire.;Sexual function. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: sexual function Questionnaire.;Emotion regulation. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: emotion regulation Questionnaire.	—

Measure

Time frame

Relapse. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: relapse Questionnaire.;Craving. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: craving Questionnaire.;Withdrawal symptoms. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: withdrawal symptoms Questionnaire.;Depression. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: depression Questionnaire.;Mania. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: mania Questionnaire.;Anxiety. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: anxiety Questionnaire.;Sleep quality. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: sleep quality Questionnaire.;Sexual function. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: sexual function Questionnaire.;Emotion regulation. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: emotion regulation Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNona Vaezi

Kermanshah University of Medical Sciences

Amirvaezi007@yahoo.com+98 83 3826 4513

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026